ADVAGEN, a Singapore based company founded in 2006 which develops and markets healthcare supplements and pharmaceuticals, is pleased to announce the approval of BiCNU® (Carmustine for injection), a chemotherapeutic product, in Singapore.

“We are indeed happy to obtain the registration approval of BiCNU® in Singapore. It has been more than 2 years since we first submitted the registration dossiers and now it can be supplied for use without requiring named patient application,” said Koh of ADVAGEN. “We will continue to ensure timely supply of the treatment to doctors and patients.”